Although avoidance of occupational triggers remains the primary step in the management of work-related allergies, immunological treatments (including biological agents and specific immunotherapy) can be regarded as potential therapeutic options for IgE-mediated diseases; for example, many studies with allergen-specific immunotherapy have been carried out on latex allergy, showing overall favorable results, at least with sublingual immunotherapy. On the other hand, only few case reports have suggested the efficacy of immunotherapy in baker's asthma as well as in laboratory animal-induced asthma. The new technologies, including component-resolved diagnosis and recombinant allergens, are expected to improve the quality and efficacy of specific immunotherapy in the future. Also the use of omalizumab may represent a suitable therapeutic choice in very selected cases of occupational allergy, as well as an approach to reduce side effects of venom immunotherapy in subjects with previous severe reactions to the treatment.
Global INnitiative for Asthma management and treatment (GINA); 2011; www.ginasthma.org last accessed Dec 2012.
2.
MaestrelliPBoschettoPFabbriLMMappCE. Mechanisms of occupational asthma. J Allergy Clin Immunol2009; 123:531–42.
3.
CowlCT. Occupational asthma. Review of Assessment, Treatment, and Compensation. Chest2011; 139:674–81.
4.
MoscatoGVandenplasOGerth van WijkR. EAACI position paper on occupational rhinitis. Respir Res2009; 10:16–22.
5.
BousquetJLockeyRMallingHJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases: a WHO Position Paper. J Allergy Clin Immunol1998; 102:558–62.
6.
KellyKJWangMLKlanknikMPetsonEL. Prevention of IgE sensitization to latex in health care workers after reduction of antigen exposure. J Occup Environ. Med2011; 53:934–39.
7.
LeynadierFHermanDVervloetDAndreC. Specific immunotherapy with standardized latex allergy extract versus placebo in allergic health workers. J Allergy Clin Immunol2000; 106:585–90.
8.
SastreJFernandez-NietoMRicoPMartinSBarberDCuestaJde las HerasMQuirceS. Specific immunotherapy with a standardized latex extract in allergic workers. J Allergy Clin Immunol2003; 111:985–94.
9.
TabarAIAndaMBonifaziFBilòMBLeynadierFFuchsTRingJGalvainSAndréC. Specific immunotherapy with standardized latex extract versus placebo in latex allergic patients. Int Arch Allergy Immunol2006; 141:369–76.
10.
NettisEDelle DonnePDi LeoE. Latex immunotherapy: state of the art. Ann Allergy Asthma Immunol2012; 109:1650–55.
11.
PatriarcaGPNuceraEPollastriniE. Sublingual desensitization: a new approach to latex allergy problem. Anest Analg2002; 95:956–60.
12.
NettisEColanardiMCSoccioAL. Double-blind, placebo-controlled study of sublingual immunotherapy in patients with latex-induced urticaria. Br J Dermatol2007; 156:674–81.
13.
Cistero BahimaASastreJEnriqueE. Tolerance and effects on skin reactivity to latex sublingual rush immunotherapy with a latex extract. J Invest Allergy Clin Immunol2004; 14:17–25.
14.
GastaminzaGAlgortaJUrielOAudicanaMFernandezESanzMLMuñozD. Randomized, double-blind controller clinical trial of sublingual immunotherapy in natural rubber latex allergic patients. Trials J2011; 12:191–201.
15.
BuyukozturkSGelincikAOzsekerFColakagluBDalM. Latex sublingual immunotherapy: can its safety be predicted. Ann Allergy Asthma Immunol2010; 104:339–45.
16.
BernardiniRPecoraSMilaniMBurasteroSE. Natural rubber latex in children: clinical and immunologic effects of 3-years sublingual immunotherapy. Eur Ann Allergy Immunol2008; 40:142–44.
17.
RollandJMO'HeirRE. Latex allergy: a model for therapy. Clin Exp Allergy2008; 38:898–912.
ArmentiaAMartin-SantosJMQuinteroA. Baker's asthma: prevalence and evaluation of immunotherapy with a wheat flour extract. Ann Allergy1990; 65:265–72.
20.
SwaminathanSHeddleRJ. Wheat flour immunotherapy in baker's asthma. Intern Med J2007; 37:663–64.
21.
CirlaAMLorenziniMACirlaPE. Specific immunotherapy and relocation in occupational allergic bakers. Gior It Med Lav Ergon2007; 29:443–45.
22.
JealH and JonesM. Allergy to rodents: an update. Clin Exp Allergy2010; 40:1593–600.
23.
WhanUSiraganianRP. Efficacy and specificity of immunotherapy with laboratory animal allergen extractsJ Allergy Clin Immunol1980;65:413–21.
24.
HansenIHormannKKlimekL. Specific immunotherapy in inhalative allergy to rat epithelium. Laryngorhinootologie2004; 83:512–15.
25.
JyoTKodomaryYKodomaiN. Therapeutic effect and titers of the specific IgE and IgG antibodies in patients with sea squirt allergy (Hoya asthma) under a long tern hyposensitization with three sea squirt antigens. J Allergy Clin Immunol1989; 83:386–93.
26.
HinojosaM. Occupational asthma due to wood. In SastreJQuirceS, eds. Occupational allergic respiratory disease. Madrid, Emisa2003; p. 335–51.
BonifaziFJutelMBilóBMBirnbaumJMullerU; EAACI Interest Group on Insect Venom Hypersensitivity. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy2005; 60:1459–70.
29.
HoffmanDREl ChoufaniSESmithMMDe GrootH. Occupational allergy to bumblebees: allergens of Bombus terrestris. J Allergy Clin Immunol2001; 108:855–60.
30.
SternAWutrichBMullerG. Successful treatment of occupational allergy to bumblebee venom after failure with honey bee venom extract. Allergy2000; 55:88–91.
31.
VegaJMMomeoIArmentiaAFernandezADe La FuenteRSánchezPSanchísME. Allergy to the pine processionary caterpillar (Thaumetopea pityocampa). Clin Exp Allergy1999; 29:1418–23.
32.
Rodriguez-MahilloALGonzalez-MunozMVegaJM. Setae from processionary moth (Thumetopoea pityocampa) contain several relevant allergens. Contact Dermatitis2012; 67:367–74.
33.
OlivieriMBiscardoCATurriSPerbelliniL. Omalizumab in persistent severe baker's asthma. Allergy2008: 63:790–91.
34.
Perez-PimientoABueso-FernandezAGarcia LoriaJRodríguez CabrerosMIMosqueraMRGarcía CuberoA. Effect of omalizumab treatment in a baker with occupational asthma. J Invest Allergy Clin Immunol2008; 18:490–91.
35.
LeynadierFDoudouOGaouarHLe GrosVBourdeixIGuyomarch-CoccoLTrunetP. Effect of omalizumab in heathcare workers with occupational latex allergy. J Allergy Clin Immunol2004; 113:360–61.
36.
GaleraCSoohunNZankarNCaimmiSGallenCDemolyP. Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment with omalizumab. J Invest Allergy Clin Immunol2009; 19:225–29.
37.
SchulzeJRoseMZielenS. Beekepers anaphylaxis: successful immunotherapy covered by omalizumab. Allergy2007; 62:963–64.
